Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Rhea-AI Summary

Oragenics (NYSE American: OGEN) announced its participation in the 3rd Nasal Formulation & Delivery Summit held April 1-3, 2025, in Boston. Chief Medical Officer Dr. James Kelly joined a panel discussion, sharing insights on intranasal drug delivery optimization and neurological treatment approaches.

The company is developing ONP-002, a novel neurosteroid designed to treat mild traumatic brain injury (mTBI) or concussion through intranasal administration, which enables rapid absorption and targeted brain delivery. The summit gathered industry leaders to discuss innovations in intranasal drug delivery, focusing on CNS therapeutics, emergency-use treatments, and infectious disease applications.

Positive

• Development of innovative intranasal drug delivery system for brain injury treatment
• Strategic presence at major industry conference demonstrating technological leadership

Negative

• None.

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA.

The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on CNS therapeutics, emergency-use treatments, and infectious disease applications. Dr. Kelly shared key insights on optimizing intranasal drug delivery, its advantages in neurological treatment, and Oragenics' approach to improving concussion patient outcomes.

Oragenics is advancing ONP-002, a novel neurosteroid designed to treat mild traumatic brain injury (mTBI) aka concussion, leveraging intranasal administration for rapid absorption and targeted brain delivery. The company’s participation in this summit underscores its commitment to innovation in non-invasive CNS therapeutics and sharing insights with the intranasal research community.

For more information about the 3rd Nasal Formulation & Delivery Summit, visit https://www.nasal-formulation-delivery.com/.

Investor Contact

Rich Cockrell
866.889.1972
ogen@cg.capital

About Oragenics, Inc.

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration. For more information, visit www.oragenics.com.

FAQ

What is Oragenics' (OGEN) main drug candidate for treating concussions?

Oragenics is developing ONP-002, a novel neurosteroid designed to treat mild traumatic brain injury (mTBI) or concussion through intranasal administration.

When and where did Oragenics (OGEN) participate in the Nasal Formulation Summit?

Oragenics participated in the 3rd Nasal Formulation & Delivery Summit held April 1-3, 2025, in Boston, MA.

What is the delivery method for Oragenics' (OGEN) concussion treatment?

The treatment uses intranasal administration for rapid absorption and targeted brain delivery.

What therapeutic areas were discussed at the 2025 Nasal Formulation Summit where OGEN presented?

The summit focused on CNS therapeutics, emergency-use treatments, and infectious disease applications in intranasal drug delivery.